The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the opportunity for more-effective alternatives—in particular, disease-modifying therapies (DMTs) that can slow the course of the disease. In response, drug developers—from big pharma to small biotech—continue to invest heavily in disease-modifying approaches owingdue to the tremendous clinical and commercial opportunity in this arena, despite decades of late-phase failures. AlthoughWhile, many uncertainties remain about the approval prospects for Biogen / Eisai’s aducanumab, and the fate of anti-amyloid MAbs from Eisai / Biogen (BAN2401) and Roche (gantenerumab) in their ongoing Phase III trials, key opinion leaders (KOLs) are cautiously optimistic about these agents and look forward to clinical results from the numerous anti-tau therapies in early- to mid-phase trials. Meanwhile, hope remains for late-phase therapies from Lundbeck / Otsuka, Avanir / Otsuka, Axsome, and Acadia that are in development for the treatment of AD agitation and psychosis, respectively. Ultimately, however, the launch of any of these agents is far from guaranteed.


  • What are the drivers and constraints in the AD market?
  • How large is the treatable AD population? What commercial uptake can be expected from Rexulti, AVP-786, AXS-05, and Nuplazid, should they launch?
  • What will be the impact of DMTs—should any of them launch—on diagnosis, drug treatment, and revenue, and which populations will be most affected?
  • What are the key learning points from the recent failure of late-phase anti-amyloid therapies, and what are experts’ opinions of the launch prospects for agents still in development?


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Alzheimer's Disease - Landscape & Forecast - Disease Landscape & Forecast

Author(s): Nakka Meher Baba Kumar; Jonathan Searles; Oliver Blandy

Jonathan W. Searles is a Senior Director in the CNS/Ophthalmology unit at DRG, overseeing the neurology research stream. Prior to joining DRG, Mr. Searles received a B.A. degree, summa cum laude, from Brandeis University; during this time, Mr. Searles conducted research projects at the Harvard University Peabody Museum and at Brandeis.

Oliver Blandy, BSc PGCE MSc, joined Decision Resources Group (DRG) as an Associate Epidemiologist in 2017. He focuses on the epidemiology of cancer.

Oliver holds an MSc from the University of Bristol where he specialized in Nutrition, Physical Activity and Public Health. He also holds a BSc in Chemistry and has a Post Graduate Certificate in Education (PGCE), both from the University of Bristol and taught general science and Advanced Chemistry in high school for two years.

Before joining the team at DRG, Oliver worked as a Research Assistant for Imperial College London where he was the lead for several studies within an NIRH funded research group that investigated healthcare associated infections and antimicrobial resistance.

Related Reports

Alzheimer's Disease - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

For the estimated 3.4 million people in the United States with Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantin...

View Details